Publications by authors named "Daniela Sirbu"

Claim this Profile
P
POLARIS: efficacy and safety of a vaginal medical device in recurrent bacterial vaginosis-a multicenter, open-label, non-controlled, study with 10 months of follow-up.
Filippo Murina, Paolo Inghirami, Marius Biriș, Daniela Sîrbu, Dionisio Franco Barattini

J Int Med Res· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real‑world study of Cerviron vaginal ovules in the treatment of cervical lesions of various etiologies.
Izabella Petre, Daniela Teodora Sirbu, Ramona Petrita, Andreea-Denisa Toma, Ema Peta

Biomed Rep· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Performance and Safety of a New Medical Device (Polybactum) for Reducing the Recurrence Rate of Bacterial Vaginosis: Protocol for a Multicenter, Open-Label, Noncontrolled International Clinical Trial (POLARIS Study).
Filippo Murina, Paolo Inghirami, Marius Biriș, Daniela Sîrbu, Dionisio Franco Barattini

JMIR Res Protoc· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Establishment of a virtual transborder tumor board for cancer patients in Central and Southeastern Europe : An initiative of the Central European Cooperative Oncology Group (CECOG).
Christiane Thallinger, Peter Berzinec, Emina Bicakcic, Adelina Dan, Gabriella Fabian, Daniela Sirbu

Wien Klin Wochenschr· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of a novel vaginal medical device in recurrent bacterial vaginosis: a multicenter clinical trial.
Filippo Murina, Ciprian Crișan, Marius Biriș, Daniela Sîrbu, Dionisio F Barattini

Minerva Ginecol· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer (TURANDOT): primary endpoint results of a randomised, open-label, non-inferiority, phase 3 trial.
Christoph Zielinski, István Láng, Moshe Inbar, Zsuzsanna Kahán, Richard Greil, Daniela Sirbu

Lancet Oncol· September 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer: interim efficacy results of the randomised, open-label, non-inferiority, phase 3 TURANDOT trial.
Istvan Lang, Thomas Brodowicz, Larisa Ryvo, Zsuzsanna Kahan, Richard Greil, Daniela Sirbu

Lancet Oncol· February 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis